Recursion Pharmaceuticals (RXRX) Stock Analysis & AI Equity Report
Recursion Pharmaceuticals (RXRX) overview
Recursion Pharmaceuticals (RXRX) stock analysis and AI equity research. For the latest completed financial year, 2024, Recursion Pharmaceuticals reported revenue of USD 58.8m and operating profit of USD -479m; the year-end share price was 6.76 USD and market capitalisation was USD 1,854m. A completed Recursion Pharmaceuticals AI equity report is available from 2 June 2026; you can buy the ready PDF or generate a fresh report with the latest available data.
Key metrics & valuation multiples
About Recursion Pharmaceuticals
Recursion Pharmaceuticals is a biotechnology company using automated biology, machine learning and large-scale data generation to discover and develop medicines. Its platform combines laboratory automation, cellular imaging, chemical and biological datasets, and computational models to identify disease biology, select drug candidates and advance internal or partnered therapeutic programmes.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Recursion Pharmaceuticals, Inc. and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Buy the ready Recursion Pharmaceuticals report
A completed Recursion Pharmaceuticals AI equity report is available from 2 June 2026. Buy the ready PDF now, or generate a new report below if you want a fresh run with the latest available data.
Or generate new Recursion Pharmaceuticals report
Generate a new Recursion Pharmaceuticals report with the latest available data for a refreshed company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.